Cost-Effectiveness of Performing Reference Ultrasonography in Patients with Deep Vein Thrombosis

Abstract

Background The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) with compression ultrasonography (CUS) may be hindered by residual intravascular obstruction after previous DVT. A reference CUS, an additional ultrasound performed at anticoagulant discontinuation, may improve the diagnostic work-up of suspected recurrent ipsilateral DVT by providing baseline images for future comparison.

Objectives To evaluate the cost-effectiveness of routinely performing reference CUS in DVT patients.

Methods Patient-level data (n = 96) from a prospective management study (Theia study; NCT02262052) and claims data were used in a decision analytic model to compare 12 scenarios for diagnostic management of suspected recurrent ipsilateral DVT. Estimated health care costs and mortality due to misdiagnosis, recurrent venous thromboembolism, and bleeding during the first year of follow-up after presentation with suspected recurrence were compared.

Results All six scenarios including reference CUS had higher estimated 1-year costs (€1,763–€1,913) than the six without reference CUS (€1,192–€1,474). Costs were higher because reference CUS results often remained unused, as 20% of patients (according to claims data) would return with suspected recurrent DVT. Estimated mortality was comparable in scenarios with (14.8–17.9 per 10,000 patients) and without reference CUS (14.0–18.5 per 10,000). None of the four potentially most desirable scenarios included reference CUS.

Conclusion One-year health care costs of diagnostic strategies for suspected recurrent ipsilateral DVT including reference CUS are higher compared to strategies without reference CUS, without mortality benefit. These results can inform policy-makers regarding use of health care resources during follow-up after DVT. From a cost-effectiveness perspective, the findings do not support the routine application of reference CUS.

Keywords

cost-effectiveness analysis - deep vein thrombosis - diagnostic imaging - recurrence - ultrasonography

Publication History

Received: 19 September 2023

Accepted: 17 November 2023

Accepted Manuscript online:
20 November 2023

Article published online:
27 December 2023

• References

• 1 Prandoni P, Lensing AW, Prins MH. et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137 (12) 955-960
• 2 Siragusa S, Malato A, Anastasio R. et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008; 112 (03) 511-515
• 3 Hamadah A, Alwasaidi T, LE Gal G. et al. Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence. J Thromb Haemost 2011; 9 (12) 2406-2410
• 4 Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2013; 11 (03) 412-422
• 5 Tan M, Velthuis SI, Westerbeek RE, VAN Rooden CJ, VAN DER Meer FJ, Huisman MV. High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis. J Thromb Haemost 2010; 8 (04) 848-850
• 6 van Dam LF, Dronkers CEA, Gautam G. et al; Theia Study Group. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood 2020; 135 (16) 1377-1385
• 7 Le Gal G, Kovacs MJ, Carrier M. et al. Validation of a diagnostic approach to exclude recurrent venous thromboembolism. J Thromb Haemost 2009; 7 (05) 752-759
• 8 Prandoni P, Cogo A, Bernardi E. et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88 (4, Pt 1): 1730-1735
• 9 Tan M, Mol GC, van Rooden CJ. et al. Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. Blood 2014; 124 (04) 623-627
• 10 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 11 Schulman S, Konstantinides S, Hu Y, Tang LV. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing: observations on NICE Guideline [NG158]. Thromb Haemost 2020; 120 (08) 1143-1146
• 12 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
• 13 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) 2247-2259
• 14 Mazzolai L, Aboyans V, Ageno W. et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39 (47) 4208-4218
• 15 Mazzolai L, Ageno W, Alatri A. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol 2022; 29 (08) 1248-1263
• 16 National Health Care Institute, the Netherlands. Appropriate Care program. Report deep vein thrombosis and pulmonary embolism (Dutch report: Zinnige Zorg, Verbetersignalement Diepe veneuze trombose en longembolie). ICD-10: chapter IX, 126, 180-182 & 187. 1 September 2021
• 17 van Dijk C, Heim N, Dik J-W. Report on reference ultrasonography and suspicions of recurrent deep vein thrombosis. (Dutch report: Resultaten onderzoek uitgangsecho's en verdenkingen op recidieven bij diepe veneuze trombose). National Health Care Institute, the Netherlands. March 2022.
• 18 van Dam LF, Gautam G, Dronkers CEA. et al. Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. J Thromb Haemost 2020; 18 (09) 2341-2348
• 19 van Dam LF, van den Hout WB, Gautam G. et al. Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. Blood Adv 2021; 5 (05) 1369-1378
• 20 Wells PS, Hirsh J, Anderson DR. et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345 (8961) 1326-1330
• 21 Fraser DG, Moody AR, Morgan PS, Martel AL, Davidson I. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002; 136 (02) 89-98
• 22 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
• 23 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
• 24 Opendata. Centraal Bureau voor de Statistiek (CBS),. StatLine. Consumentenprijzen; prijsindex 2015 = 100. Accessed December 5, 2023 at: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83131ned/table
• 25 Mansour S, Alotaibi G, Wu C, McMurtry MS. Trends in admission rates and in-hospital stay for venous thromboembolism. Thromb Res 2017; 156: 149-154
• 26 Dentali F, Di Micco G, Giorgi Pierfranceschi M. et al. Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. Ann Med 2015; 47 (07) 546-554
• 27 Wan T, Rahmani A, Hanakova M. et al. Reducing emergency department visits in patients with deep vein thrombosis: introducing a standardised outpatient treatment pathway. BMJ Open Qual 2021; 10 (02) e001123
• 28 van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014; 30 (05) 829-837
• 29 Desai A, Desai A, Calixte R. et al. Comparing length of stay between patients taking rivaroxaban and conventional anticoagulants for treatment of venous thromboembolism. Lung 2016; 194 (04) 605-611
• 30 Kosten in Kaart. Bewustzijnsproject. 2018 . Accessed December 5, 2023 at: www.bewustzijnsproject.nl/stars
• 31 Beoordelings- en verantwoordingsrapport dbc-pakket 2017 van de Nederlandse Zorgautoriteit (NZa). Bijlage 1: Kengetallen en statistiek. 2016 . Accessed December 5, 2023 at: https://puc.overheid.nl/nza/doc/PUC_13003_22/1/
• 32 Huisman MV, Büller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95 (03) 498-502
• 33 Bikdeli B, Wang Y, Jimenez D. et al. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999-2015. JAMA 2019; 322 (06) 574-576
• 34 Huisman MV, Barco S, Cannegieter SC. et al. Pulmonary embolism. Nat Rev Dis Primers 2018; 4: 18028
• 35 Barco S, Mahmoudpour SH, Valerio L. et al. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2020; 8 (03) 277-287
• 36 Barco S, Valerio L, Ageno W. et al. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO mortality database and of the CDC multiple cause of death database. Lancet Respir Med 2021; 9 (01) 33-42
• 37 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
• 38 van der Wall SJ, van der Pol LM, Ende-Verhaar YM. et al. Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. Eur Respir Rev 2018; 27 (150) 180094
• 39 Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147 (11) 766-774
• 40 Mühlbacher AC, Sadler A. The probabilistic efficiency frontier: a framework for cost-effectiveness analysis in Germany put into practice for hepatitis C treatment options. Value Health 2017; 20 (02) 266-272
• 41 Caro JJ, Nord E, Siebert U. et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010; 19 (10) 1117-1127
• 42 Zorginstituut Nederland. Cost-effectiveness in practice. 2015 . Accessed December 5, 2023 at: https://english.zorginstituutnederland.nl/publications/reports/2015/06/16/cost-effectiveness-in-practice
• 43 Opendata. Centraal Bureau voor de Statistiek (CBS), StatLine. Gezonde levensverwaching;. vanaf 1981 . Accessed December 5, 2023 at: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/71950ned/table
• 44 AlBader M, Le Gal G, Rodger MA, Kovacs MJ, Delluc A. Yield of ultrasonography in patients with or without post-thrombotic syndrome for diagnosis of suspected recurrent ipsilateral deep vein thrombosis. J Thromb Haemost 2020; 18 (10) 2654-2657
• 45 Bernardi E, Camporese G, Büller HR. et al; Erasmus Study Group. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 2008; 300 (14) 1653-1659
• 46 Hussain T. ed. Chapter 14 Concepts of costs. In: Engineering Economics. Kolkata: Laxmi Publications Pvt. Ltd.; 2010